Emerging Company Profile
Tallac: linking antibodies to DNA-triggered innate immunity
Emerging Company Profile: Tallac launches with $62M A round, pipeline of antibody-TLR9 agonist conjugates
Tallac has launched with a $62 million series A round and a solid tumor platform enabling I.V. administration of immunostimulatory TLR9 agonist via conjugation to antibodies.
Dec 9, 2020 | 1:24 AM GMT